Sparsentan (RE-021) cas 254740-64-2

Sparsentan, also known as RE-021, PS433540 and DARA-a, is a Dual angiotensin II and endothelin A receptor antagonist. Retrophin intends to develop RE-021 for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy. RE-021, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.

RAAS Inhibitors Related Prodcuts:

Azilsartan; VTP-27999 TFA; Eprosartan Mesylate; Telmisartan; Valsartan; Enalapril Maleate; Temocapril hydrochloride; Fimasartan; Fosinopril Sodium; Olmesartan medoxomil